Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Ferrlecit Cancer Study With Epoetin Will Enter Phase II By Year-End

Executive Summary

Watson Pharmaceuticals plans to initiate a Phase II trial of Ferrlecit for cancer patients by the year-end.

You may also be interested in...



Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics

Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)

Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics

Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)

Novartis Lamisil, Janssen Sporanox Liver Toxicity Warning Added To Labeling

Novartis Lamisil patients should be assessed for pre-existing liver disease before receiving the antifungal tablets, revised labeling recommends.

Related Content

UsernamePublicRestriction

Register

PS038391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel